Sentinel node biopsy for prostate cancer

report from a consensus panel meeting

Henk G. van der Poel (Corresponding Author), Esther M Wit, Cenk Acar, Nynke S van den Berg, Fijs W.B. van Leeuwen, Renato A Valdes Olmos , Alexander Winter, Friedhelm Wawroschek , Fredrik Liedberg, Steven MacLennan, Thomas Lam, Sentinel Node Prostate Cancer Consensus Panel Group

Research output: Contribution to journalArticle

17 Citations (Scopus)
5 Downloads (Pure)

Abstract

Objective:
To explore the evidence and knowledge gaps in sentinel node biopsy (SNB) in prostate cancer by a consensus panel of experts.

Methods:
A two-round Delphi survey among experts was followed by a consensus panel meeting of 16 experts in February 2016. Agreement voting was performed using the RAND/University of California, Los Angeles Appropriateness Methodology on 150 statements in 9 domains. The disagreement index based on the interpercentile range-adjusted for symmetry score was used to assess consensus and non-consensus among panel members

Results:
Consensus was obtained on 91 of 150 (61%) statements. Main outcomes were: 1. The results from an extended lymph node dissection (eLND) are still considered the gold standard and SN detection should be combined with eLND at least in intermediate and high risk prostate cancer patients; 2. The role of SN detection in low risk prostate cancer is unclear; 3. Future studies should contain oncological endpoints as number of positive nodes outside the eLND template, false negative and false positive SN procedures, and recurrence-free survival. A high rate of consensus was obtained regarding outcome measures of future clinical trials on SNB (89%). Consensus on tracer technology was only obtained in 47% of statements reflecting a need for further research and standardization in this area.
The low level evidence in the available literature and the composition of mainly SN users in the panel constitute the major limitations of the study.

Conclusions:
Consensus on a majority of elementary statements on SN detection in prostate cancer was obtained. Therefore the results from this consensus report will provide a basis for the design of further studies in the field.


Original languageEnglish
Pages (from-to)204–211
Number of pages8
JournalBJU International
Volume120
Issue number2
Early online date8 Mar 2017
DOIs
Publication statusPublished - 1 Aug 2017

Fingerprint

Prostatic Neoplasms
Lymph Node Excision
Biopsy
Los Angeles
Politics
Outcome Assessment (Health Care)
Clinical Trials
Technology
Recurrence
Survival
cyhalothrin
Research

Keywords

  • consensus meeting report
  • sentinel node biopsy
  • extended lymph node dissection
  • #prostate cancer
  • #PCSM

ASJC Scopus subject areas

  • Medicine(all)

Cite this

van der Poel, H. G., Wit, E. M., Acar, C., van den Berg, N. S., van Leeuwen, F. W. B., Olmos , R. A. V., ... Sentinel Node Prostate Cancer Consensus Panel Group (2017). Sentinel node biopsy for prostate cancer: report from a consensus panel meeting. BJU International, 120(2), 204–211. https://doi.org/10.1111/bju.13810

Sentinel node biopsy for prostate cancer : report from a consensus panel meeting. / van der Poel, Henk G. (Corresponding Author); Wit, Esther M; Acar, Cenk; van den Berg, Nynke S; van Leeuwen, Fijs W.B.; Olmos , Renato A Valdes ; Winter, Alexander; Wawroschek , Friedhelm ; Liedberg, Fredrik; MacLennan, Steven; Lam, Thomas; Sentinel Node Prostate Cancer Consensus Panel Group .

In: BJU International, Vol. 120, No. 2, 01.08.2017, p. 204–211.

Research output: Contribution to journalArticle

van der Poel, HG, Wit, EM, Acar, C, van den Berg, NS, van Leeuwen, FWB, Olmos , RAV, Winter, A, Wawroschek , F, Liedberg, F, MacLennan, S, Lam, T & Sentinel Node Prostate Cancer Consensus Panel Group 2017, 'Sentinel node biopsy for prostate cancer: report from a consensus panel meeting', BJU International, vol. 120, no. 2, pp. 204–211. https://doi.org/10.1111/bju.13810
van der Poel HG, Wit EM, Acar C, van den Berg NS, van Leeuwen FWB, Olmos RAV et al. Sentinel node biopsy for prostate cancer: report from a consensus panel meeting. BJU International. 2017 Aug 1;120(2):204–211. https://doi.org/10.1111/bju.13810
van der Poel, Henk G. ; Wit, Esther M ; Acar, Cenk ; van den Berg, Nynke S ; van Leeuwen, Fijs W.B. ; Olmos , Renato A Valdes ; Winter, Alexander ; Wawroschek , Friedhelm ; Liedberg, Fredrik ; MacLennan, Steven ; Lam, Thomas ; Sentinel Node Prostate Cancer Consensus Panel Group . / Sentinel node biopsy for prostate cancer : report from a consensus panel meeting. In: BJU International. 2017 ; Vol. 120, No. 2. pp. 204–211.
@article{4901a77f59944c5eaf8acf5043d7bc3d,
title = "Sentinel node biopsy for prostate cancer: report from a consensus panel meeting",
abstract = "Objective:To explore the evidence and knowledge gaps in sentinel node biopsy (SNB) in prostate cancer by a consensus panel of experts.Methods:A two-round Delphi survey among experts was followed by a consensus panel meeting of 16 experts in February 2016. Agreement voting was performed using the RAND/University of California, Los Angeles Appropriateness Methodology on 150 statements in 9 domains. The disagreement index based on the interpercentile range-adjusted for symmetry score was used to assess consensus and non-consensus among panel members Results:Consensus was obtained on 91 of 150 (61{\%}) statements. Main outcomes were: 1. The results from an extended lymph node dissection (eLND) are still considered the gold standard and SN detection should be combined with eLND at least in intermediate and high risk prostate cancer patients; 2. The role of SN detection in low risk prostate cancer is unclear; 3. Future studies should contain oncological endpoints as number of positive nodes outside the eLND template, false negative and false positive SN procedures, and recurrence-free survival. A high rate of consensus was obtained regarding outcome measures of future clinical trials on SNB (89{\%}). Consensus on tracer technology was only obtained in 47{\%} of statements reflecting a need for further research and standardization in this area.The low level evidence in the available literature and the composition of mainly SN users in the panel constitute the major limitations of the study.Conclusions:Consensus on a majority of elementary statements on SN detection in prostate cancer was obtained. Therefore the results from this consensus report will provide a basis for the design of further studies in the field.",
keywords = "consensus meeting report, sentinel node biopsy, extended lymph node dissection, #prostate cancer, #PCSM",
author = "{van der Poel}, {Henk G.} and Wit, {Esther M} and Cenk Acar and {van den Berg}, {Nynke S} and {van Leeuwen}, {Fijs W.B.} and Olmos, {Renato A Valdes} and Alexander Winter and Friedhelm Wawroschek and Fredrik Liedberg and Steven MacLennan and Thomas Lam and {Sentinel Node Prostate Cancer Consensus Panel Group}",
note = "Acknowledgements We thank all contibutors to the Delphi Survey for their input, as well as the companies Karl Storz Endoskope (Germany) and Intuitive Surgical (USA) for making the consensus meeting possible.",
year = "2017",
month = "8",
day = "1",
doi = "10.1111/bju.13810",
language = "English",
volume = "120",
pages = "204–211",
journal = "BJU International",
issn = "1464-4096",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Sentinel node biopsy for prostate cancer

T2 - report from a consensus panel meeting

AU - van der Poel, Henk G.

AU - Wit, Esther M

AU - Acar, Cenk

AU - van den Berg, Nynke S

AU - van Leeuwen, Fijs W.B.

AU - Olmos , Renato A Valdes

AU - Winter, Alexander

AU - Wawroschek , Friedhelm

AU - Liedberg, Fredrik

AU - MacLennan, Steven

AU - Lam, Thomas

AU - Sentinel Node Prostate Cancer Consensus Panel Group

N1 - Acknowledgements We thank all contibutors to the Delphi Survey for their input, as well as the companies Karl Storz Endoskope (Germany) and Intuitive Surgical (USA) for making the consensus meeting possible.

PY - 2017/8/1

Y1 - 2017/8/1

N2 - Objective:To explore the evidence and knowledge gaps in sentinel node biopsy (SNB) in prostate cancer by a consensus panel of experts.Methods:A two-round Delphi survey among experts was followed by a consensus panel meeting of 16 experts in February 2016. Agreement voting was performed using the RAND/University of California, Los Angeles Appropriateness Methodology on 150 statements in 9 domains. The disagreement index based on the interpercentile range-adjusted for symmetry score was used to assess consensus and non-consensus among panel members Results:Consensus was obtained on 91 of 150 (61%) statements. Main outcomes were: 1. The results from an extended lymph node dissection (eLND) are still considered the gold standard and SN detection should be combined with eLND at least in intermediate and high risk prostate cancer patients; 2. The role of SN detection in low risk prostate cancer is unclear; 3. Future studies should contain oncological endpoints as number of positive nodes outside the eLND template, false negative and false positive SN procedures, and recurrence-free survival. A high rate of consensus was obtained regarding outcome measures of future clinical trials on SNB (89%). Consensus on tracer technology was only obtained in 47% of statements reflecting a need for further research and standardization in this area.The low level evidence in the available literature and the composition of mainly SN users in the panel constitute the major limitations of the study.Conclusions:Consensus on a majority of elementary statements on SN detection in prostate cancer was obtained. Therefore the results from this consensus report will provide a basis for the design of further studies in the field.

AB - Objective:To explore the evidence and knowledge gaps in sentinel node biopsy (SNB) in prostate cancer by a consensus panel of experts.Methods:A two-round Delphi survey among experts was followed by a consensus panel meeting of 16 experts in February 2016. Agreement voting was performed using the RAND/University of California, Los Angeles Appropriateness Methodology on 150 statements in 9 domains. The disagreement index based on the interpercentile range-adjusted for symmetry score was used to assess consensus and non-consensus among panel members Results:Consensus was obtained on 91 of 150 (61%) statements. Main outcomes were: 1. The results from an extended lymph node dissection (eLND) are still considered the gold standard and SN detection should be combined with eLND at least in intermediate and high risk prostate cancer patients; 2. The role of SN detection in low risk prostate cancer is unclear; 3. Future studies should contain oncological endpoints as number of positive nodes outside the eLND template, false negative and false positive SN procedures, and recurrence-free survival. A high rate of consensus was obtained regarding outcome measures of future clinical trials on SNB (89%). Consensus on tracer technology was only obtained in 47% of statements reflecting a need for further research and standardization in this area.The low level evidence in the available literature and the composition of mainly SN users in the panel constitute the major limitations of the study.Conclusions:Consensus on a majority of elementary statements on SN detection in prostate cancer was obtained. Therefore the results from this consensus report will provide a basis for the design of further studies in the field.

KW - consensus meeting report

KW - sentinel node biopsy

KW - extended lymph node dissection

KW - #prostate cancer

KW - #PCSM

U2 - 10.1111/bju.13810

DO - 10.1111/bju.13810

M3 - Article

VL - 120

SP - 204

EP - 211

JO - BJU International

JF - BJU International

SN - 1464-4096

IS - 2

ER -